CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Northside Hospital, Inc.
Children's Oncology Group
Northside Hospital, Inc.
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Kura Oncology, Inc.
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Stanford University
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
Hackensack Meridian Health
Dana-Farber Cancer Institute
University Hospital, Caen
AvenCell Therapeutics, Inc.
Daiichi Sankyo
St. Jude Children's Research Hospital
Medical University of South Carolina
CERo Therapeutics Holdings, Inc.